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ABSTRACT
Here, we report on a novel bispeciﬁc antibody-derivative, designated RTX-CD47, with unique capacity for CD20-
directed inhibition of CD47-SIRPa “don’t eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv
antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Single agent treatment
with RTX-CD47 triggered signiﬁcant phagocytic removal of CD20pos/CD47pos malignant B-cells, but not of
CD20neg/CD47pos cells, and required no pro-phagocytic FcR-mediated signaling. Importantly, treatment with
RTX-CD47 synergistically enhanced the phagocytic elimination of primary malignant B cells by autologous
phagocytic effector cells as induced by therapeutic anticancer antibodies daratumumab (anti-CD38),
alemtuzumab (anti-CD52) and obinutuzumab (anti-CD20). In conclusion, RTX-CD47 blocks CD47 “don’t eat me”
signaling by cancer cells in a CD20-directed manner with essentially no activity towards CD20neg/CD47pos cells






Solid and hematological malignancies exploit the inhibitory
CD47/SIRPa pathway to evade elimination by the immune sys-
tem.1–3 Speciﬁcally, binding of tumor-overexpressed CD47
with phagocyte-expressed SIRPa inhibits phagocytic removal
of cancer cells and reduces the immunogenic processing of
tumor antigens by macrophages and dendritic cells.4–6 Conse-
quently, both innate and adaptive anticancer immunity is sup-
pressed. Correspondingly, CD47 overexpression is associated
with poor clinical prognosis in various malignancies.3,7
Antibodies that block CD47/SIRPa interaction are of poten-
tial clinical interest and have yielded promising preclinical
anti-tumor activity in various murine tumor models. CD47-
blocking antibodies were shown to enhance the induction of
antibody-dependent cellular phagocytosis (ADCP) of cancer
cells upon treatment with therapeutically used anticancer anti-
bodies. For instance, cotreatment of rituximab with the CD47-
blocking murine antibody B6H12 synergized the phagocytic
elimination of xenografted human CD20pos NHL cancer cells
in various mouse tumor models in the absence of noticeable
toxicity.8 Correspondingly, humanized CD47-blocking anti-
bodies Hu5F9-G4 and CC-90002 are currently being evaluated
in Phase 1 clinical trials in patients with advanced solid and
hematological malignancies (ClinicalTrials.gov identiﬁer:
NCT02216409 and NCT02367196).
However, the lack of CD47-related toxicity as observed in
mouse models may not accurately reﬂect the impact of a gener-
alized blockade of CD47 in humans, as the antibody B6H12
does not cross-react with mouse CD47.9 CD47 is broadly
expressed on normal cells, including mesenchymal stromal cells
and blood cells, in particular erythrocytes and platelets.9 Thus,
a generalized blockade of CD47/SIRPa interaction may result
in phagocytosis and immunological processing of normal
healthy cells. Therefore, ubiquitous on-target/off-tumor inhibi-
tion of CD47/SIRPa interaction by conventional CD47-block-
ing antibodies in humans may associate with toxicity.
Moreover, the abundant expression of CD47 throughout the
human body is likely to form a massive “sink” that may limit
tumor accretion of CD47-blocking antibodies.
Recently, two bispeciﬁc antibodies (bsAb) designed to
enhance the selectivity of CD47-blocking activity towards
CD20- and CD19-expressing cells, respectively.10,11 The CD20-
directed/CD47-blocking bsAb was of the so-called dual
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variable-domain immunoglobulin (DVD-Ig) format, whereas
the CD19-directed/CD47-blocking bsAb was of the so-called
kλ-body format. Both these bsAbs contained a functional IgG1
Fc effector domain which appeared to be required for their
pro-phagocytic activity. However, the presence of functional Fc
domains in these bsAbs may result in premature off-target acti-
vation of Fc-receptor (FcR)-expressing phagocytes which is
associated with systemic toxicity.12 Further, off-target Fc/FcR-
binding may reduce the accretion of these bsAbs at the tumor
cell surface.
Here, we report on an alternate bsAb format termed RTX-
CD47 that consists of a CD47-blocking single chain fragment
of variable regions (scFv) antibody fragment genetically fused
in tandem to a CD20-targeting scFv derived from rituximab.
This bispeciﬁc tandem scFv (bi-scFv) does not contain an Fc
domain and was designed to have monovalent binding speciﬁc-
ity for CD20 and CD47, respectively (for schematic representa-
tion see Fig. 1A). RTX-CD47 was constructed to promote
CD20-directed blockade of CD47-SIRPa “don’t eat me” signal-
ing towards cancer cell types that express both CD20 and
CD47, while preventing toxicity associated with untimely FcR
cross-linking.
Results and discussion
The bi-scFv RTX-CD47 construct was designed to promote
CD20-directed blockade of CD47-SIRPa “don’t eat me” signal-
ing towards cancer cells that express both CD20 and CD47. In
the bi-scFv, both scFvs retained functionality as evidenced by
the binding of RTX-CD47 to CHO.CD47 cells but not parental
CHO cells (Suppl. Fig 1A) and its binding to CEM.CD20 cells
but not parental CEM cells (Suppl. Fig.1B). Next, the potential
enhanced avidity due to simultaneous binding to CD20 and
CD47 by RTX-CD47 was evaluated on a panel of cell lines. Sig-
niﬁcant binding of RTX-CD47 was only detected towards
CD20pos/CD47pos malignant B-cell lines, with only minimal
Figure 1. CD20-directed blocking of CD47-SIRPa interaction by RTX-CD47 (A) Schematic representation of RTX-CD47 comprising a CD20-targeting scFv derived from ritux-
imab genetically fused to a CD47-blocking scFv and lacking an Fc domain. (B) RTX-CD47 selectively binds to CD20posCD47pos cell lines and not to CD20negCD47pos cell
lines. Binding of RTX-CD47 to the cells was determined by ﬂow cytometry using an HA tag antibody. (C) RTX-CD47 binding to Ramos CD20pos/CD47pos cells in the pres-
ence or absence of CD20-blocking antibody RTX (5 mg/mL) and/or CD47-blocking antibody B6H12 (5 mg/mL). Binding of RTX-CD47 could only be blocked by simulta-
neously adding excess amounts of CD20- and CD47-competing MAbs. (D) SIRPa-Fc binding to CD47 was blocked by RTX-CD47 on CD20/CD47 double positive cells
(WIL2S and Z138) and not on CD20negCD47pos (SEM and DLD1). Binding of SIRPa-Fc to the cell surface of the cells was determined by ﬂow cytometry using human recom-
binant SIRPa-Fc (5mg/ml) followed by staining with mouse anti-SIRPa and Alexa Fluor 488-conjugated goat anti-mouse IgG. (E) Bar graph displaying the MFI of the SIRPa-
Fc binding as in (D), with the addition of a condition in which SIRPa-Fc binding was restored by an excess of the CD20-competing antibody rituximab (5 mg/ml) prior to
RTX-CD47 binding on CD20pos/CD47pos WIL2S tumor cells.
e1386361-2 P. E. VAN BOMMEL ET AL.
binding to CD20neg/CD47pos cancer cells (Fig. 1B). Binding of
RTX-CD47 to CD20pos/CD47pos tumor cells was partially
reduced by competing CD20 or CD47 antibody, but was only
abrogated in the presence of both CD20- and CD47-competing
mAbs (Fig. 1C). Thus, RTX-CD47 has enhanced avidity for
CD20pos/CD47pos tumor cells. These ﬁndings are in concor-
dance with previously published results with bsAbs, including
those targeting CD47, showing an avidity effect upon concur-
rent binding to both antigens on the same cell.10,13,14
Of note, bsAbs can cooperatively bind to the target cells, via
a process in which binding to antigen 1 strongly promotes
binding to antigen 2, even when the afﬁnity for the latter anti-
gen is low.10,13,14 In this respect, our binding data suggests that
binding of RTX-CD47 to CD20 is needed in order to achieve
efﬁcient CD47/SIRPa blocking. In line with this mode-of-
action, incubation with RTX-CD47 completely blocked the
binding of recombinant human SIRPa-Fc to CD20pos/CD47pos
cancer cells, but did not inhibit binding of SIRPa-Fc to
CD20neg/CD47pos cancer cells (Fig. 1D). Furthermore, inhibi-
tion of CD20-speciﬁc binding of RTX-CD47 by rituximab
abrogated the inhibitory effect of RTX-CD47 on SIRPa-Fc
binding (Fig. 1E). Taken together, RTX-CD47 appears to have
CD20-restricted capacity for blocking CD47/SIRPa interaction
towards CD20pos/CD47pos cells.
Next, we evaluated the capacity of RTX-CD47 to enhance
ADCP activity of clinically used anticancer antibodies using
mixed cultures of monocyte-derived macrophages and ﬂuores-
cently-labeled cancer cells. Of note, macrophages are the key
effector cells for ADCP induced by clinically used anticancer
antibodies. Treatment with RTX-CD47 induced macrophage-
mediated phagocytosis of 4 out of the 6 CD20pos malignant B
cell lines (Fig. 2A, B). Importantly, treatment with RTX-CD47
also signiﬁcantly triggered phagocytosis of primary patient-
derived malignant B cells by autologous macrophages
(Fig. 2C). Furthermore, RTX-CD47, signiﬁcantly induced
phagocytosis by granulocytes of CD20pos/CD47pos double-posi-
tive CEM cells, but not CD47 single-positive CEM (Fig. 2D).
Of note, granulocytes are the most prevalent phagocytic cell
type in humans, albeit less capable of engulﬁng complete (or
more than one) tumor cells than macrophages. In a panel of
tumor cell lines, only CD20pos/CD47pos double-positive tumor
cells were phagocytosed by granulocytes (Fig. 2E). Importantly,
single-agent treatment of a panel of primary patient-derived B
malignant cells with RTX-CD47 also signiﬁcantly triggered
Figure 2. RTX-CD47 has single-agent pro-phagocytic activity towards CD20pos cancer cells. (A) Representative photos for macrophage phagocytosis assay with Daudi cells
treated with RTX-CD47. RTX-CD47 induced macrophage-mediated phagocytosis of 4 out of the 6 CD20pos cancer cell lines. (B) RTX-CD47 triggered phagocytosis of primary
patient-derived malignant B cells by autologous macrophages. (D) RTX-CD47 enhanced PMN-mediated phagocytosis of CEM.CD20 cells but not of parental CEM cells. (E)
RTX-CD47 induced phagocytosis of all CD20/CD47 double positive cell lines in this cell panel and had no phagocytic activity on CD20negCD47pos cancer cell lines. (F) RTX-
CD47 triggered granulocyte-mediated phagocytosis of primary patient-derived B malignant cells. (G) Phagocytosis induced by RTX-CD47 on WIL2 S cells is blocked by the
addition of RTX F(ab’)2 (5 mg/ml).
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granulocyte-mediated phagocytosis compared to medium con-
trol (Fig. 2F). Phagocytosis induced by RTX-CD47 was depen-
dent on simultaneous binding to CD20 and CD47 as co-
incubation with excess amounts of RTX-derived F(ab’)2 anti-
body fragments inhibited phagocytosis (Fig. 2G).
Thus, RTX-CD47 has prominent single-agent pro-phago-
cytic activity that involves blocking CD47 ‘don’t eat me’ signal-
ing in a CD20-restricted manner. This CD20-restricted pro-
phagocytic activity of RTX-CD47 is fully independent of FcR
signaling and only due to blocking of CD47/SIRPalpha interac-
tion. Such CD47-selective pro-phagocytic activity is in line
with the effect of ‘Fc-less’ F(ab’)2 versions of CD47 mAbs.
8,15
Notably, the pro-phagocytic activity of the above-mentioned
DVD-Ig and kλ-body bsAb formats partly relies on FcR signal-
ing. Indeed, the pro-phagocytic activity of the CD20-CD47
DVD-Ig bsAb was completely inhibited by pre-incubation with
a cocktail of FcR-blocking agents.10
The CD20-restricted blocking of CD47 “don’t eat me” signal-
ing by RTX-CD47may be of particular clinical use as an adjuvant
approach to promote phagocytosis induction by therapeutic anti-
cancer antibodies. Here, a therapeutic anticancer antibody that
targets malignant B-cells recruit appropriate immune effector
cells, while RTX-CD47 potentiates the ADCP effect in a CD20-
restricted manner. To explore the feasibility of this approach,
mixed cultures of allogeneic macrophages and (CD20pos/
CD38pos) Daudi cells were treated with a suboptimal dose of RTX
or an anti-CD38 antibody (both containing a human IgG1 Fc
domain) and RTX-CD47. For both RTX and the anti-CD38
mAb, co-treatment with RTX-CD47 signiﬁcantly augmented
macrophage-mediated phagocytosis of Daudi lymphoma cells
compared to single-agent treatment (Fig. 3A). Further, co-treat-
ment of CEM.CD20 cells, but not CEM cells, with a suboptimal
and non-saturating dose of RTX and RTX-CD47 signiﬁcantly
enhanced macrophage-mediated phagocytosis (Fig. 3B). In con-
trast, co-treatment of CEM.CD20 with the anti-CD38 antibody
and RTX-CD47did not potentiate phagocytosis, as CEM.CD20
cells lack expression of CD38 (Fig.3B and Suppl. Fig. 1C). Thus,
at non-saturating RTX doses the combination with RTX-CD47 is
able to augment CD20-restricted phagocytosis of cancer cells.
Interestingly, the subset of macrophages that were found to
phagocytose target cells also engulfed signiﬁcantly more tumor
cells per macrophage upon combination treatment of RTX-CD47
with rituximab or anti-CD38 antibody (Fig. 3C, D). Thus, adju-
vant treatment with RTX-CD47 indeed appears to augment mac-
rophage-mediated phagocytosis/ADCP as induced by therapeutic
anticancer antibodies.
In analogous experiments with granulocytes, co-treatment of
BJAB Burkitt lymphoma cells with therapeutic antibodies and
RTX-CD47 also signiﬁcantly augmented phagocytosis compared
to single- agent treatment with low suboptimal concentrations of
anti-CD38 antibody, alemtuzumab and rituximab (Fig. 3E). In
contrast, co-treatment of BJAB cells with control EGFR-targeted
antibody cetuximab and RTX-CD47 did not induce phagocytosis
(Fig. 3E). To further validate the relevance of this adjuvant activ-
ity, phagocytosis of primary patient–derived B-cell malignancies,
expressing CD47, CD20 and CD52 (data not shown), by autolo-
gous patient-derived granulocytes was evaluated. Co- treatment
of mixed cultures with alemtuzumab and RTX-CD47 strongly
induced phagocytosis in 5 out of 5 of these primary malignant B-
cell samples, an effect signiﬁcantly stronger than treatment with
either alemtuzumab or RTX-CD47 alone (Fig. 3F). Similar results
were obtained when allogeneic granulocytes from healthy donors
were used, with single treatment with RTX-CD47 signiﬁcantly
increasing granulocyte-mediated phagocytosis of 6 out of 7 pri-
marymalignant B-cell samples (Suppl. Fig. 1D).
As detailed above, combination of RTX-CD47 with low and
non-saturating dose of RTX is capable of augmenting ADCP
activity. However, the RTX concentration applied in patients
may inhibit RTX-CD47 binding due to direct competition for
the binding to the CD20 epitope. To circumvent this potential
problem, we evaluated the adjuvant activity of RTX-CD47 in
combination with obinutuzumab, a humanized anti-CD20
antibody that is known to target a non-overlapping epitope on
the extracellular loop of CD20.16 In a CD20 binding competi-
tion assay, no inhibitory effect of RTX-CD47 on CD20 binding
by FITC-labeled obinutuzumab was detected (Suppl. Fig. 1E).
In contrast, RTX-CD47 did partially block CD20 binding of
FITC-labeled rituximab (Suppl. Fig. 1F). Rituximab and obinu-
tuzumab did compete for CD20 binding with each other
(Suppl. Fig. 1E, F), suggesting the presence of steric hindrance
in the full IgG antibody format that does not occur when com-
bining obinutuzumab with the bi-scFv RTX-CD47 format. Of
note, obinutuzumab is glycoengineered to have superior pro-
phagocytic activity compared to rituximab17 and was recently
FDA-approved for the treatment of CLL. In an NHL cell line
panel, RTX-CD47 treatment indeed signiﬁcantly potentiated
macrophage-mediated phagocytosis by obinutuzumab in 3 out
4 B-cell leukemia cell lines and in CEM.CD20 cells (Fig. 3G),
whereas combination treatment with RTX enhanced phagocy-
tosis only in 1 out of 4 NHL cell lines (Suppl. Fig. 1G). Impor-
tantly, combination of RTX-CD47 with obinutuzumab also
augmented phagocytosis of primary malignant B cells by autol-
ogous primary patient-derived macrophages with signiﬁcantly
increased macrophage-mediated phagocytosis in comparison
to RTX co- treatment (Fig. 3H). Similar results were obtained
in granulocyte phagocytosis assays, with RTX-CD47 potently
enhancing the phagocytic activity by obinutuzumab in 6 out of
6 CD20posCD47pos cell lines (Fig. 3I). Thus, combination of
RTX-CD47 with obinutuzumab is feasible and may augment
its therapeutic anticancer activity.
In conclusion, RTX-CD47 blocks CD47/SIRPa “don’t eat
me” signaling in a CD20-restricted manner, resulting in the
selective phagocytic removal of cancer cells by human phago-
cytes and enhances phagocytosis in combination with various
therapeutic anticancer antibodies. RTX-CD47 requires binding
to CD20 in order to block CD47/SIRPa interaction due to its
monovalent binding afﬁnity for each antigen. This feature
reduces the risk of toxicity that would occur upon off-target
phagocytosis with ubiquitous CD47 blocking. Further, the
absence of a functional IgG1 Fc-domain has the inherent
advantage of being devoid of toxicity issues related to prema-
ture on-target/off-tumor triggering of FcR-mediated Antibody-
Dependent Cellular Cytotoxicity (ADCC) and antibody-
dependent phagocytosis (ADCP) or Complement Dependent
Cytotoxicity (CDC). Thus, RTX-CD47 represents a prototype
tumor-selective pro-phagocytic therapeutic protein that may be
particularly useful to safely augment the tumoricidal activity of
anticancer monoclonal antibodies.
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Materials and methods
Antibodies
Fluorescent-conjugated murine mAbs directed against human
CD16 (clone 3G8), CD20 (clone HI47), CD52 (clone HI186),
CD7 (clone MEM-186) where purchased from Immunotools,
anti- human CD47 (clone B6H12) from Abcam and anti-HA
tag from GenScript. Fluorescently labeled secondary antibodies;
mouse anti-SIRPa (Abcam) and goat anti-mouse IgG (Life
technologies). Cetuximab (CTX, human IgG1- chimeric anti-
EGFR), alemtuzumab (IgG1 humanized anti-CD52) and rituxi-
mab (RTX, human IgG1 chimeric anti-CD20) were from
Merck KGaA, Genzyme and Roche, respectively. A human
IgG1 chimeric daratumumab-analogue (anti-human CD38)
was produced in- house using published VH and VL data and
standard antibody engineering technology. F(ab’)2 fragments of
Figure 3. RTX-CD47 enhances ADCP by therapeutic anticancer antibodies. (A) RTX-CD47 synergized with therapeutic mAb in mediating phagocytosis of Daudi cells by
macrophages. (B) RTX-CD47 enhanced (RTX mediated) phagocytosis of CEM.CD20 cells but not of parental CEM cells. (C) Representative photos of single macrophages
engulﬁng V450-labeled target cells upon combined treatment with RTX-CD47 and RTX. (D) Quantiﬁcation of phagocytic index from (A) showing average number of
engulfed tumor cell per macrophage. (E) Combined treatment with RTX-CD47 and therapeutic antibodies (cetuximab, daratumumab, alemtuzumab (5 ng/ml) and rituxi-
mab (10 ng/ml)) signiﬁcantly augmented phagocytosis levels BJAB cells. (F) Combined treatment with RTX-CD47 and alemtuzumab (1 mg/ml) signiﬁcantly augmented
phagocytosis levels of primary b-cell malignancies. (G) RTX-CD47 treatment potentiated macrophage-mediated phagocytosis of CD20pos cancer cell lines by obinutuzu-
mab. (H) RTX-CD47 potentiated obinutuzumab mediated phagocytosis of primary patient-derived MCL cells by autologous macrophages. (I) RTX-CD47 treatment potenti-
ated PMN- mediated phagocytosis of CD20pos cancer cell lines by obinutuzumab.
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rituximab were generated using the Pierce TM F(ab’)2 Micro
Preparation Kit (Thermo Scientiﬁc) according to manufac-
turer’s instructions.
Construction of CD47-blocking tandem bs-scFv
RTX-CD47 was constructed by inserting DNA fragments
encoding the indicated scFv antibody fragments in either of the
two multiple cloning sites (MCS) of plasmid pEE14-bs-scFv.
This plasmid is equipped with a kappa light chain leader
sequence for protein excretion into the culture supernatant and
adds an in-frame N-terminal HA detection tag to the protein.
MCS#1 and MCS#2 are separated by DNA sequences encoding
a 25 amino acid ﬂexible linker sequence. In short: a 749 bps
DNA fragment encoding a CD20-directed scFv antibody frag-
ment (scFvRTX) derived from rituximab was directionally
inserted into the SﬁI and NotI restriction sites of MCS#1. Sub-
sequently, a 750 bps DNA fragment encoding a CD47-blocking
scFv derived from MAb MABL18,19 was inserted in-frame using
the XhoI and XbaI restriction sites of MCS#2, yielding end
product pEE14-bs-scFvRTX-CD47. The full sequence of the L-













































TCAAACGTGCCGCTTAA. These sequence data have been
submitted to the GenBank databases under accession number.
The tandem bs-scFv antibody was produced by transfecting
HEK293 production cells (ATCC; Manassas, VA) with plasmid
pEE14-scFvCD47:scFvRTX using the Fugene-HD reagent
(Promega). Supernatants of transfected HEK293 cells were har-
vested, cleared by centrifugation and stored at ¡20C.
Cell lines and patient-derived malignant cells
All cell lines used in this study were obtained from the Ameri-
can Type Culture Collection (Manassas, VA). CD20pos malig-
nant B-cell lines used are: WIL2 S (hereditary spherocytosis),
Z138 (Mantle cell lymphoma) and Burkitt lymphoma cell lines
Ramos, Raji, BJAB and CD20 transfected CEM cells. CD20neg
cell lines used are: CEM (T-ALL), SEM (B-ALL), DND41 (T-
ALL), Karpas 45 (T-ALL) and DLD1 (colorectal adenocarci-
noma). Cells were cultured in RPMI culture medium (Lonza)
supplemented with 10% fetal calf serum (FCS, Thermo Scien-
tiﬁc) at 37C in humidiﬁed 5% CO2 containing atmosphere.
Expression levels of CD20 and CD47 were evaluated by ﬂow
cytometry using appropriate ﬂuorescently labeled antibodies
and an Accuri C6 ﬂow cytometer (BD Biosciences). Cell line
CEM.CD20 ectopically expressing human CD20 was kindly
provided by Department of pathology, UMCG. Of note, ectopic
expression of CD20 by CEM.CD20 cells did not alter the
endogenous levels of CD47 expression (data not shown).
Peripheral blood mononuclear cells (PBMCs) from patient
blood were isolated by using gradient centrifugation and then
phenotyped with CD3, CD19, CD20, CD38 and CD52. Primary
human leukocytes were obtained from healthy volunteers using
the ammonium chloride lysis method. PBMCs were obtained
from healthy volunteers after informed consent using density
gradient centrifugation. Monocytes were isolated from PBMCs
using anti-CD14-coated magnetic beads (Miltenyi Biotec,
USA). For generation of immature macrophages, monocytes (3
£ 106/ml) were cultured in the presence of 50 U/ml GM-CSF
and 50 U/ml M-CSF for 7 d, and then primed with LPS and
IFN-g. This study was carried out in The Netherlands in accor-
dance with the applicable rules concerning the review of
Research Ethics Committees and informed consent.
Binding assays
CD20-speciﬁc binding by RTX-CD47 was evaluated on a cell
line panel of CD20posCD47pos and CD20negCD47pos tumor cell
types using a secondary FITC-conjugated anti-HA antibody
(GenScript). Simultaneous binding of RTX-CD47 to CD20 and
CD47 was evaluated by incubating CD20posCD47pos Ramos
cells in the presence (or absence) of excess amounts (5 mg/mL)
of either rituximab (anti-CD20) or MAb B6H12 (anti-CD47)
or both. CD20-speciﬁc binding activity of RTX-CD47 was
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further evaluated by comparing its binding characteristics to
parental CEM and CEM.CD20 cells. Blocking of CD47-SIRPa
interaction by bs-scFv RTX-CD47 was assessed by evaluating
its ability to prevent binding of recombinant human SIRPa-Fc
(5mg/ml, R&D systems) to CD47pos cancer cells (5.0 £ 105
cells) by ﬂow cytometry using appropriate ﬂuorescently labeled
secondary antibodies. All incubations were for 1 h at 4C and
followed by 2 washes with PBS.
Granulocyte-mediated phagocytosis assay
Tumor-directed inhibition of CD47/SIRP-alpha “don’t eat
signaling” by bs-scFv RTX-CD47 was evaluated by its
capacity to induce speciﬁc phagocytosis of DiD- ﬂuores-
cently labeled tumor cells by IFN-g activated granulocytes.
In short, human granulocytes were pre-activated for 1 h
with IFN-g (50 ng/ml) at 37C and then co-cultured with
cancer cells at an effector to target cell ratio of 1 to 1.
Phagocytosis cancer cell lines: mixed cultures were
incubated for 2 h at 37C in the presence (or not) of anti-
cancer antibodies cetuximab (5 ng/ml), daratumumab
(5 ng/ml), alemtuzumab (5 ng/ml), rituximab (10 ng/ml))
and (or not) bs-scFv RTX-CD47, bs-scFv CD7- CD47 and
indicated combinations thereof. Phagocytosis of primary
patient–derived B-cell malignancies: mixed cultures were
incubated over night at 37C in the presence of bs-scFv
RTX- CD47. To assess the capacity of bs-scFv RTX-CD47
to enhance the efﬁcacy of alemtuzumab, mixed cultures
were incubated 4 h at 37C in the presence of alemtuzumab
(1 mg/ml) and/or bs-scFv RTX- CD47. Afterwards cells
were washed and stained with CD16-FITC antibody. Phago-
cytosis of cancer cells by the granulocytes under the various
conditions indicated was evaluated by determining the
percentage of CD16pos/DiDpos granulocytes using ﬂow
cytometry.
Macrophage-mediated phagocytosis assay
Cell proliferation reagent V450-stained tumor cells were
mixed with pre-seeded macrophages at E:T ratio 5:1 in 96-
well plates. Mixed cells were treated either with control
medium or medium contained RTX-CD47 in the presence
or absence of therapeutic mAbs (RTX, 2.5 mg/ml,daratumu-
mab, 0.5 mg/ml, obinutuzumab, 2.5 mg/ml) for 3 h. After
gently washing tumor cells away, adherent macrophages
were left in the well for further analysis with ﬂuorescence
microscopy. The phagocytic index was calculated using the
following formula: phagocytic index D (total number of
phagocytosed tumor cells)/(number of macrophages that
have phagocytosed tumor cells).
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